Ipca Laboratories Limited, established in 1949 and headquartered in Mumbai, Maharashtra, stands as a prominent player in the pharmaceutical industry. Known for its manufacturing and export of pharmaceutical formulations and active pharmaceutical ingredients (APIs), Ipca Laboratories has developed a strong reputation for its commitment to quality and innovation. Operating across six continents and more than 120 countries, Ipca Laboratories provides a broad spectrum of products that address various therapeutic needs, including pain management, rheumatology, antimalarials, and hair care therapy.
Ipca is a fully integrated pharmaceutical company, boasting an extensive product range that includes over 350 formulations and 80 APIs. Its manufacturing capabilities are both advanced and diverse, allowing it to produce a wide array of APIs, such as theobromine, acetylthiophene, and p-bromotoluene. In formulations, Ipca manufactures oral liquids, tablets, dry powders, and capsules to meet global demand. Ipca’s manufacturing facilities are approved by key regulatory bodies, including the US FDA, UK MHRA, and WHO Geneva, underscoring the company’s commitment to high standards and its competitive presence in the global pharmaceutical market.
Latest News on Ipca Laboratories
The Nifty Pharma Index showed a positive trend on November 12, 2024, rising by 0.67%, driven by strong performances across several key pharmaceutical stocks. Ipca Laboratories emerged as one of the top gainers within the index, marking an impressive 4.55% increase in its stock value. This gain reflects a favorable market response and strong investor interest, positioning Ipca Laboratories as a prominent contributor to the day’s overall positive performance in the pharmaceutical sector.
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | |
| Promoters + | 46.29% | 46.29% | 46.30% | 46.30% | 46.30% |
| FIIs + | 9.86% | 10.27% | 10.51% | 10.85% | 10.83% |
| DIIs + | 34.72% | 34.19% | 34.05% | 33.46% | 33.90% |
| Government + | 0.32% | 0.32% | 0.32% | 0.32% | 0.32% |
| Public + | 8.80% | 8.93% | 8.82% | 9.07% | 8.64% |
| No. of Shareholders | 95,930 | 82,809 | 81,165 | 84,753 | 82,975 |
The shareholding pattern of Ipca Laboratories over the past year highlights a stable distribution among its major stakeholders, with minor shifts reflecting market dynamics and investor interest. As of September 2024, promoters held a consistent stake of 46.30%, demonstrating their ongoing confidence and stability in the company. Foreign Institutional Investors (FIIs) showed an upward trend, increasing from 9.86% in September 2023 to 10.83% in September 2024, indicating growing interest from international investors.
Domestic Institutional Investors (DIIs), on the other hand, exhibited a slight decrease from 34.72% in September 2023 to 33.90% by September 2024. This gradual decline among DIIs suggests a possible reallocation of assets. The government’s shareholding remained unchanged at 0.32%, maintaining a minimal yet consistent presence. Public shareholding experienced fluctuations, reaching 9.07% in June 2024 but settling at 8.64% by September 2024. The total number of shareholders varied across the periods, ending with 82,975 in September 2024, reflecting the active engagement and evolving investment preferences of individual investors in Ipca Laboratories.
Below are the trading platforms that you can use to purchase Ipca Laboratories shares:
➤ Zerodha
➤ Upstox
➤ Groww
➤ AngelOne
➤ ICICIDirect
| When | Maximum Price | Minimum Price |
| November 2024 | 1,583.05 | 1,376.57 |
| December 2024 | 1,598.88 | 1,390.33 |
As we move into November 2024, Ipca Laboratories’ stock is projected to reach a maximum of ₹1,583.05, with a minimum of ₹1,376.57. By December 2024, expectations suggest a slight increase, with Ipca Laboratories potentially reaching a peak of ₹1,598.88, while the lower range may stabilize around ₹1,390.33.
| When | Maximum Price | Minimum Price |
| January 2025 | 1,614.87 | 1,242.21 |
| February 2025 | 1,631.19 | 1,254.76 |
| March 2025 | 1,665.44 | 1,281.11 |
| April 2025 | 1,648.95 | 1,268.42 |
| May 2025 | 1,600.92 | 1,231.48 |
| June 2025 | 1,672.96 | 1,286.90 |
| July 2025 | 1,640.16 | 1,261.66 |
| August 2025 | 1,690.89 | 1,300.68 |
| September 2025 | 1,711.18 | 1,316.29 |
| October 2025 | 1,755.67 | 1,350.51 |
| November 2025 | 1,799.56 | 1,384.28 |
| December 2025 | 1,880.54 | 1,446.57 |
As we move through 2025, Ipca Laboratories’ stock is projected to experience gradual growth. Starting in January, it could range between ₹1,614.87 and ₹1,242.21, and by June, it may peak at ₹1,672.96 with a minimum of ₹1,286.90. In the latter half of the year, the stock is expected to see higher values, reaching up to ₹1,799.56 in November and ultimately closing December with a maximum of ₹1,880.54 and a minimum of ₹1,446.57.
| When | Maximum Price | Minimum Price |
| January 2026 | 1,936.96 | 1,489.97 |
| February 2026 | 1,888.53 | 1,452.72 |
| March 2026 | 1,926.30 | 1,481.77 |
| April 2026 | 1,965.62 | 1,512.01 |
| May 2026 | 1,946.15 | 1,497.04 |
| June 2026 | 1,994.81 | 1,534.47 |
| July 2026 | 1,955.69 | 1,504.38 |
| August 2026 | 2,016.18 | 1,550.91 |
| September 2026 | 2,056.50 | 1,581.93 |
| October 2026 | 2,109.97 | 1,623.06 |
| November 2026 | 2,162.72 | 1,663.63 |
| December 2026 | 2,216.79 | 1,705.22 |
| When | Maximum Price | Minimum Price |
| January 2027 | 2,238.96 | 1,722.28 |
| February 2027 | 2,296.37 | 1,766.44 |
| March 2027 | 2,385.93 | 1,835.33 |
| April 2027 | 2,339.14 | 1,799.34 |
| May 2027 | 2,271.01 | 1,746.93 |
| June 2027 | 2,373.21 | 1,825.54 |
| July 2027 | 2,326.67 | 1,789.75 |
| August 2027 | 2,398.63 | 1,845.10 |
| September 2027 | 2,482.59 | 1,909.68 |
| October 2027 | 2,547.13 | 1,959.33 |
| November 2027 | 2,610.81 | 2,008.32 |
| December 2027 | 2,676.08 | 2,058.52 |
| When | Maximum Price | Minimum Price |
| January 2028 | 2,729.60 | 2,099.69 |
| February 2028 | 2,799.59 | 2,153.53 |
| March 2028 | 2,908.78 | 2,237.52 |
| April 2028 | 2,851.74 | 2,193.65 |
| May 2028 | 2,768.68 | 2,129.76 |
| June 2028 | 2,893.27 | 2,225.59 |
| July 2028 | 2,836.54 | 2,181.96 |
| August 2028 | 2,924.27 | 2,249.44 |
| September 2028 | 3,026.62 | 2,328.17 |
| October 2028 | 3,105.31 | 2,388.70 |
| November 2028 | 3,182.94 | 2,448.42 |
| December 2028 | 3,262.52 | 2,509.63 |
| When | Maximum Price | Minimum Price |
| January 2029 | 3,327.77 | 2,559.82 |
| February 2029 | 3,413.10 | 2,625.46 |
| March 2029 | 3,546.21 | 2,727.85 |
| April 2029 | 3,476.67 | 2,674.36 |
| May 2029 | 3,375.41 | 2,596.47 |
| June 2029 | 3,527.30 | 2,713.31 |
| July 2029 | 3,458.14 | 2,660.11 |
| August 2029 | 3,565.09 | 2,742.38 |
| September 2029 | 3,689.87 | 2,838.36 |
| October 2029 | 3,785.81 | 2,912.16 |
| November 2029 | 3,880.45 | 2,984.96 |
| December 2029 | 3,977.47 | 3,059.59 |
| When | Maximum Price | Minimum Price |
| January 2030 | 4,057.01 | 3,120.78 |
| February 2030 | 4,161.04 | 3,200.80 |
| March 2030 | 4,323.32 | 3,325.63 |
| April 2030 | 4,238.55 | 3,260.42 |
| May 2030 | 4,115.10 | 3,165.46 |
| June 2030 | 4,300.28 | 3,307.91 |
| July 2030 | 4,215.96 | 3,243.04 |
| August 2030 | 4,346.35 | 3,343.34 |
| September 2030 | 4,498.47 | 3,460.36 |
| October 2030 | 4,615.43 | 3,550.33 |
| November 2030 | 4,730.82 | 3,639.09 |
| December 2030 | 4,849.09 | 3,730.07 |
In 2030, Ipca Laboratories’ stock prices are expected to see a steady upward trend. In January, prices may range between ₹4,057.01 and ₹3,120.78. As we move through mid-year, by June, values could reach a high of ₹4,300.28, with a lower end of ₹3,307.91. Progressing into the later months, projections suggest a rise to ₹4,615.43 in October, with a minimum of ₹3,550.33. By December, Ipca Laboratories’ stock may peak at ₹4,849.09, with a possible low of ₹3,730.07, indicating Strong growth throughout the year.
Ipca Laboratories Financial Condition:
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
| Sales + | 4,619 | 5,395 | 5,797 | 6,204 | 7,662 | 8,212 |
| Expenses + | 3,715 | 3,843 | 4,472 | 5,272 | 6,338 | 6,846 |
| Operating Profit | 904 | 1,552 | 1,325 | 932 | 1,324 | 1,367 |
| OPM % | 20% | 29% | 23% | 15% | 17% | 17% |
| Other Income + | 65 | 59 | 54 | 123 | 17 | 32 |
| Interest | 20 | 12 | 11 | 48 | 141 | 131 |
| Depreciation | 210 | 209 | 232 | 262 | 357 | 387 |
| Profit before tax | 739 | 1,389 | 1,136 | 745 | 843 | 881 |
| Tax % | 18% | 17% | 20% | 34% | 37% | |
| Net Profit + | 604 | 1,141 | 890 | 479 | 523 | 558 |
| EPS in Rs | 23.99 | 44.94 | 34.85 | 18.58 | 21.57 | 22.74 |
| Dividend Payout % | 10% | 9% | 11% | 22% | 19% |
Ipca Laboratories has demonstrated steady financial growth over recent years, with notable shifts across key metrics. From March 2020 to the trailing twelve months (TTM) ending in 2024, sales have shown a strong upward trend, increasing from ₹4,619 crore to ₹8,212 crore, indicating robust revenue growth. Operating profits, however, have fluctuated, with an Operating Profit Margin (OPM) reaching its peak of 29% in March 2021, before settling at 17% by the TTM of 2024, reflecting shifts in operating expenses, which grew from ₹3,715 crore in 2020 to ₹6,846 crore in TTM 2024.
Net profits also saw variations, peaking in March 2021 at ₹1,141 crore but adjusting to ₹523 crore in March 2024 and ₹558 crore in the TTM, partly due to rising interest costs, which jumped significantly from ₹20 crore in 2020 to ₹131 crore in the TTM. Meanwhile, the company’s tax rate rose from 18% in March 2020 to 37% in recent periods, impacting the bottom line. Earnings per Share (EPS) followed a similar trajectory, with a high of ₹44.94 in 2021 and ending at ₹22.74 in the TTM. Dividend payouts also adjusted, with a notable increase to 22% in 2023 before reducing to 19% in 2024, reflecting Ipca Laboratories’ balance between reinvestment and rewarding shareholders.
FAQs
What is the current market capitalization of Ipca Laboratories?
As of November 14th, 2024, the market cap is quite strong, standing at ₹38,881 Crores.
Ipca Laboratoires’s shares are currently trading at ₹1,536 as of November 14th, 2024.
Looking ahead, the share price is expected to range between ₹1,446.57 to ₹1,880.54 by December 2025.
The long-term outlook is optimistic, with a projected range of ₹3,730.07 to ₹4,849.09 by December 2030.
What is the current Price-to-Earnings (PE) ratio of Ipca Laboratories?
Currently, the stock’s PE ratio is at a reasonable 73.3.
Also Read
- Kalpataru Projects International Share Price Target 2025, 2026 to 2030
- Puravankara Ltd Share Price Target 2024, 2025 to 2030
- Godrej Agrovet Ltd Share Price Target 2024, 2025 to 2030
Conclusion
In conclusion, Ipca Laboratories has positioned itself as a key player in the global pharmaceutical market, known for its strong focus on APIs and formulations, with consistent investor confidence and a solid market presence. Recent stock gains within the Nifty Pharma Index highlight its relevance and potential, with shareholding patterns showing stable promoter confidence, increased foreign institutional interest, and some reallocation by domestic investors. Price projections suggest a steady upward trend, with 2025 starting around ₹1,614.87 in January and potentially reaching ₹1,880.54 by December, while by 2030, prices could peak at ₹4,849.09. Financially, Ipca has demonstrated growth in sales, although profit margins have faced pressure, with operating margins dipping from 29% in 2021 to 17%, affected by rising expenses and tax rates. Overall, Ipca Laboratories remains a resilient and appealing long-term investment choice, with promising growth projections in the coming years.
What did we learn?
- 1 Latest News on Ipca Laboratories
- 2 Shareholdings Patterns of Ipca Laboratories
- 3 How to Buy Ipca Laboratories Shares in India?
- 4 Ipca Laboratories Share Price Prediction: 2024 – 2030
- 4.1 Ipca Laboratories Share Price Target 2024
- 4.2 Ipca Laboratories Share Price Target 2025
- 4.3 Ipca Laboratories Share Price Prediction 2026
- 4.4 Ipca Laboratories Share Price Target 2027
- 4.5 Ipca Laboratories Share Price Target 2028
- 4.6 Ipca Laboratories Share Price Target 2029
- 4.7 Ipca Laboratories Share Price Prediction 2030
- 5 Ipca Laboratories Financial Condition:
- 6 FAQs
- 6.1 What is the current market capitalization of Ipca Laboratories?
- 6.2 What is the current share price of Ipca Laboratories?
- 6.3 What is the share price target for Ipca Laboratories in 2025?
- 6.4 What is the share price target for Ipca Laboratories in 2030?
- 6.5 What is the current Price-to-Earnings (PE) ratio of Ipca Laboratories?
- 7 Conclusion
